recognize the the team another couple first I for X would a and everyone. our prior difficult with beginning XXXX year, strong afternoon, be quarters XX% good order pleased chain am and we challenges. to over the Brett, to of significant you, the due preparing of the outlook year supply growth announce Xtant for Thank
million addressing toward to new our to raising to $XXX consequently, million. we range to these our [ [ are are first million $XXX progress by $XXX confident revenue quarter, completing million guidance -- ] $XXX challenges ] However, $XXX about [ from and of ] a
quite Keep in these part declined are consecutive period becoming mind, with of of product we We XX% XXXX. we pleased quarters the the prior acquired in over assets Medical. lines Surgalign of Moreover, a growth X Xtant to
stem first the start losses then sense. and priority makes investing it to was building and Our where
some that getting this Our acquisition. a collect the risk team our Surgalign for of has the More our Xtant in hardware old of lines on transition investment thesis off business. a done the moving theme products which that specifically, job terrific customers us main was helped flywheel at have were
towards where From to adult contributions the in help updated also us network systems. no Moreover, replace new way previous business, our distribution significant we aging improve acquired XXX growth, IDN our from there With fixation opportunity biologics. a saw that sales. international define are we Surgalign products during dramatically we days revenue new distributors as with spine pulling our organic an best-in-class growth retentive through contracts, affordable platform nice a excluding and in perspective, the business growth an X-spine durable could saw
the this growth in was quarter. year. organic first as low prior calls, revenue And I quarterly of in over quarter First [indiscernible] conference anticipated year mentioned X we the last half
market, we organic to double challenges new introduce anticipate However, XXXX, half second the we during growth products supply as digits. of abate, and our chain reaching delivering the
that. reiterate Let me
to we robust Xtant. trajectory each the organic for growth growth double-digit half ensure X of are addressing thus and second areas a are of reach XXXX. our them key in growth There will and that affected We have far, actively sustainable
year. Happily, April, again. extremely an The to up building line of we last back back product a business strong This are short levels are since cells. as this inventory first been and of has stem August are up supply
strong OEM new membrane challenges. lines first year last we line primarily well we We the will year, to allografts, the sales. fiscal roll OEM sales half an product This Second, our in pick half X had as this like -- that will our of XXXX. out of OEM year in will be [indiscernible] of supply due do second
the by products rate. exspine our Third, growth products hardware cannibalization organic old core dampens of reline acquired our
rebuild to However, to as to profitability newer, and our I a of lines. positive this infrastructure improved more Surgalign support Surgalign adjusted investments the future upgrade our mentioned to plan part our EBITDA despite surgeons From perspective, before, is the broader product were we growth.
expense growth. So expenses of improvements of expect adjusted see drive with build will that in how will QX beyond. revenue from and to time, give margin overview platform an gross and us as we perspective, long-term percentage combined this I'll in to At decline we operating operating now growth an a sustainable provide a EBITDA
one, our are market strategic Starting with product pipeline deep of introductions; distribution on: innovate reminder, greater every new adjacent four, a and three, with key Like new products. robust a expand access; healthy, growth continually pillars and we contract X focused new As network acquisitions. products. penetration; two, organization,
to of which profile. the course expanded During offering product our from we enhanced turnaround, X categories biologics X, our product our
cells, bone that orthobiologics, synthetics, wound as Xtant viable amniotic category, month, biologics a which matrix are known sixth factor. complete growth company for offers of membrane the advanced allografts surgical include new in we allograft, care. This Moreover, and stem released otherwise past DBM, a applications line only
business. currently this an solution a Xtant far someone but product branded products with can else we well believe sold us, our product provide of small profitably as grow as is OEM product that line for previously line distributed superior fantastic focused producer. surgical we the that made a on our side a Xtant repair This as
our self-sustainability. of year year XXXX is Fiscal
others the on The we second to we own chain. than products where from much this of not way plan to we products our control a half standards out profitable that produce roll year, do in more relying supply
outpatient the several Through are a opportunities. side, and development settings. have started product, on of we Also device. and motion finishing we ASC reviving the side, very is This in reimbursement soft hardware Corterra PMA-based Coflex new by a the interlaminar exciting fantastic was preservation rollout that is that the hardware Surgalign. stabilization the acquisition, on system the Additionally, are the fixation posterior we good
contract And expanding we are on now that will completing rollout, the distribution in QX fully anticipate process pillar network The by we next this which completed of year. focuses be and access. our of
offers GPOs access cover platform IDNs XXX to all U.S. XX% of than that Our the approximately beds in more and
primary the continuing will more plan new years at get In adds, distribution number our for includes XXX past, to the distributors. distributors by focus XX total we per of quarter. look penetration to now greater expand than to Today, but In have distributors addition, agents least network distributor be into focused we on today. opportunistic our we
sales stickier we that product products, lines What a distributor become and of found the Medical. our more the distributor as for Xtant they is have
where is IM Now of significant products serve impact. OEM term serve we potentially places turning to dynamics to the our expanding beyond that other markets third and verticals have a can build for pillar, spine orthopedics. verticals leveraging the about learn adjacent with those an we manufacturing, specific longer and goal into our markets. different is Xtant One Through
traction ankle, foot gained and markets. within joint reconstruction and trauma orthopedic the have We
addition both markets. care serve advanced and the the chronic surgical we wound repair our With of now amniotic products, can tissue
either similar final acquisitions. specifically, IDN our leveraging of offering are distributors help or products over growth either focuses companies agreements complete to achieve undercapitalized in that we companies are targeting XXX us nationally, through Our scale. are By selling More targeted subscale. and or growth additional provide XXXX, our who our pillar our platform on are we XXX that acquisitions targeting
believe to distribution to a our more to, maybe XX distributors, can those XXX their only them nationwide or technology have acquisitions. the what take XX to agreements meet Surgalign with to innovative and and companies them We Coflex similar a we IDN access For may on and of instance, think have about our taking potential, help access we their technologies contracts, or company get give done say, network. that XXX
X first, key We're characteristics: capabilities, targets Our that regenerative greater focus looking us capabilities. at on based give particularly in or companies biologics. acquisition is technologies on
spine help offering offerings. at look businesses in preservation motion will and we Additionally, that fixation complete Xtant's
that that long-term profitable we advantage will demand. And are or our acquired stringent making biologics a then targeted our sound, profitable distribution companies Targets take cost become to strategic criteria production believe will fit our expand fast-growing take us third, businesses and robust flow, step goals. network We to through X part that platform or future longer-term that can company. acquisitions capacity. cash allow Second, within our and that of being of unique margin closer can achieving believe synergies. We
support To Financial $XX sustainable long-term purchased those time of to with long-term revenue better continues potentially debt and Xtant million to entrepreneurs the our growth bigger and Furthermore, is win MidCap the our pleased value. we believe initiatives, even [ it we and from increase are when grow. are ] other companies to as million. fast of to growth will they win driving maximizing over owners to Xtant $XX committed shareholder allow pace then
share, capital our eye positive Moreover, to greater of quarter well with more access operating flow positions achieving execute on an XXXX. cash strategy fourth us during and capture further market to
XXXX. to represents revenue increased approximately XXXX $XXX we annual XX% to a million range million. outlook new This guidance year to $XXX of Finally, full of compared our to XX% year range full increased growth
anticipate organic will growth quarter the XXXX. of continuing half beginning we our second of into accelerate that, XXXX second the Within in and
by expect second environment first cell the the chain. business affected XXXX adversely and revitalizing supply a by by shortage of will Surgalign the be of that XXXX stem our driven was market and temporary We the in in this quarter half supply normalized
Moving we less Moreover, this supply on producer and should options coupled of our self-sustaining improve that and expanded brings during an patient fourth are transformative products be will positive We line believe help operationally actions allow self-reliance more will product chain margin us treatment becoming by us with outside these get XXXX. dramatically diverse forward, of to for biologics. importantly, production population. profile, controlling to our operating focused our large becoming reliant a of quarter a control. Most and own larger growing producing we the flow believe cash additional
Now quarter turn financial results. XXXX will first over to discuss I'd like who our call to Scott, the
